WSP.TO 2.79COST -9.67TECK.B.TO -0.01ORCL 4.74SHOP.TO -0.2CDNS -12.175BRK.B -2.1ARGT -0.39
Amgen Inc. (AMGN)

NASDAQ:AMGN

Amgen Inc. (AMGN)

437.23
-6.89 (1.55%)
as of Sep 4, 2026, 8:00:00 pm Market Open.
107 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 4, 2026, 12:00 am

This summary was created by AI, based on 16 opinions in the last 12 months.

Amgen Inc. (AMGN-Q) is seen as a well-managed and innovative biotech company that has shown impressive performance in its recent earnings reports, surpassing expectations in both revenue and profit margins. Analysts highlight a robust pipeline, with 15 of its products experiencing double-digit sales growth, which suggests strong ongoing demand for their offerings. Additionally, Amgen's work in GLP-1 drugs, including a potential game-changing product in phase 3 testing, has garnered positive sentiment, alongside its attractive dividend yield. Overall, experts suggest holding the stock for long-term gains, with a favorable outlook considering the current market trends and the company's positioning within the biotech sector.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
Gilead, GILD
BUY

Amgen Inc.(AMGN)

Aug 11, 2023

He took some money out of tech and put it into healthcare, which has seen an increase lately. He just added Amgen who delieverd a terrific report. He will continue to rally in the second half this year, will outperform tech.

Photo of Bill Baruch, Founder, Blue Line CapitalBill Baruch, Founder, Blue Line Capital
Owned
Unlock Rating
$262.45

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Aug 08, 2023

A long-term fine business and just reported good earnings. It's not in tech or industrials, so it has more stickiness. They made positive plans in their drug pipeline. Seasonally, now is the right time to buy biotech

(Analysts’ price target is $256.05)
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
Owned
Unlock Rating
$261.69

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Jul 28, 2023

He bought it last week to diversify and get more exposure in pharmaceuticals. They report next week. Compare to Abbvie which just surprised with drug sales. There's some FT overhang, but shares have been bottoming out recently. If they announce good results, investors will chase this next week.

Photo of Bill Baruch, Founder, Blue Line CapitalBill Baruch, Founder, Blue Line Capital
Owned
Unlock Rating
$236.86

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Amgen Inc.(AMGN)

Apr 28, 2023

Facing a patent crisis as proprietary tech is challenged.
Shares have recently sold off.
Will take time to see how prospects play out.
Good hold, but other places to invest for new investors. 

Photo of Darren SissonsDarren Sissons
No
Unlock Rating
$239.76

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Jan 11, 2023
Granddaddy of biotech. Even better than it used to be. Very deep bench of drugs. New acquisition will add growth on top of already-decent growth. Very strong financials. Income opportunity, stability, and some growth not yet fully priced in. Yield is 3.14%, well covered at 42%, increased by 11% average annually over 5 years. (Analysts’ price target is $268.80)
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$272.35

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Dec 28, 2022
Share have given up a lot since its Horizon Therapeutics deal, making it an opportunity.
Photo of Guy AdamiGuy AdamiUnlock Rating
$261.42

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Dec 12, 2022
Today, they said they are buying Horizon Therapeutics for $27.8 billion. This deal should close quickly, since there's little overlap of these companies' drugs. Initially, he thought the price was high, but now he likes the deal. An established, big biotech that bought a younger biotech with exciting drugs at a 15% premium. Amgen wants HT's portfolio of drugs treating rare diseases and well-covered by insurance, therefore lucrative. HT's drugs will benefit from Amgen's worldwide distribution.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$275.24

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

Oct 11, 2022
(A Top Pick Nov 01/21, Up 20%) Bought it to be defensive for 2022. They announced a new facility in San Francisco. The future looks positive.
Photo of Andrew PyleAndrew Pyle
Owned
Unlock Rating
$246.26

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

Oct 11, 2022
(A Top Pick Nov 01/21, Up 20%) Bought it to be defensive for 2022. They announced a new facility in San Francisco. The future looks positive.
Photo of Andrew PyleAndrew Pyle
Owned
Unlock Rating
$246.26

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Amgen Inc.(AMGN)

Sep 15, 2022
(A Top Pick Nov 03/20, Up 4.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AMGN has triggered its stop at $228. To remain disciplined, we recommend covering the holding at this time.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$227.47

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Aug 15, 2022
Some of their key drugs are coming off patent, so he likes how they're making key buys of companies like CCXI, which would give Amgen exposure to drugs for auto-immune diseases and inflammatory conditions. CCXI has one drug on the market to treat blood vessel inflammation and a handful of phase 1 treatments including ulcerative colitis. The deal is good for Amgen.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$251.08

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Amgen Inc.(AMGN)

Apr 21, 2022
(A Top Pick Nov 03/20, Up 17.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AMGN is progressing well. We now recommend trailing up the stop (from $218) to $228.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$257.24

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Apr 12, 2022
Are big worries about inflation and the economy and war. So, be in the US dollar, which should rally if the world goes deflationary. This is also a big name, and there's a massive rotation into the drug companies. He target $272. It pays a 3% dividend. (Analysts’ price target is $242.24)
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$249.53

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Amgen Inc.(AMGN)

Mar 22, 2022
(A Top Pick Nov 03/20, Up 7.8%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with AMGN is progressing well. To remain disciplined, we now recommend trailing up the stop (from $205) to $218.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$236.64

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Nov 01, 2021
This name has been beaten up and now offers value. There is concern that markets could experience a pull-back and one way to play that is this one. It is a large entity in the healthcare space and has under-performed its space. As we push out of the pandemic we are going to see increased regular appointments and more diagnostics. This company offers decent value. (Analysts’ price target is $243.05)
Photo of Andrew PyleAndrew Pyle
Owned
Unlock Rating
$209.88

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 46 to 60 of 166 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NXE.TO 0.16$14.89
ATD.TO 0.09$82
T.TO -0.01$13.39
KKR -2.03$107.73
CSU.TO -17.42$3023.96
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

WSP.TO 2.79$186.86
COST -9.67$915.74
TECK.B.T… -0.01$13.39
ORCL 4.74$158.78
SHOP.TO -0.2$200.76

Popular Articles

Latest Sell Signals

LULU -21.19$100.58
CVX -2.72$208.6
ZQQ.TO 0.46$199.22
SOXX 17.66$519.86
AAPL -8.24$319.97

Most Recent Experts

Brian Madden

Brian Madden

First Avenue Investment Counsel

Kim Bolton

Kim Bolton

Black Swan Dexteritas

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like